Tanruprubart
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Guillain-Barre Syndrome
Conditions
Guillain-Barre Syndrome
Trial Timeline
Sep 12, 2025 → Jun 30, 2028
NCT ID
NCT07020819About Tanruprubart
Tanruprubart is a phase 3 stage product being developed by Annexon for Guillain-Barre Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07020819. Target conditions include Guillain-Barre Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07020819 | Phase 3 | Recruiting |
Competing Products
2 competing products in Guillain-Barre Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Efgartigimod Alfa-Fcab + Intravenous Immunoglobulin (IVIg) | Argenx | Phase 2 | 49 |
| ANX005 + Placebo | Annexon | Phase 3 | 72 |